Browse the evidence

High-dose GLP-1 receptor agonists and treatment of patients with higher baseline BMI are associated with a significantly increased risk of ventricular arrhythmias (VAs).

If you are taking a high dose of a GLP-1 medication (like the maximum weight-loss doses of Ozempic or Saxenda), especially if you have a higher body weight, there is a slightly increased risk of ventricular arrhythmias. Doctors should monitor these patients more closely. However, this risk is specific to high doses and higher BMI, not the standard doses used for diabetes.

Oral semaglutide is associated with a significantly lower risk of incident atrial fibrillation (AF), while dulaglutide shows an increasing trend toward higher AF risk compared to controls.

Among GLP-1 medications, oral semaglutide (Rybelsus) may actually lower the risk of atrial fibrillation, while dulaglutide (Trulicity) might slightly increase it. This difference is drug-specific and not seen with all GLP-1s. If you have a history of AF, discuss the specific drug choice with your doctor.

GLP-1 receptor agonists (GLP-1 RAs) significantly increase the risk of gastrointestinal adverse events, specifically intestinal obstruction and perioperative aspiration, due to delayed gastric emptying.

If you are taking a GLP-1 medication (like Ozempic or Wegovy) and have surgery or an endoscopy, tell your medical team. You may need to adjust your fasting time or pause the medication to prevent stomach contents from entering your lungs, which is a known risk of these drugs.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly with weight-loss focused dosing and specific agents like liraglutide.

Be aware that GLP-1 medications can increase the risk of gallstones, especially if you are losing weight rapidly. Report any abdominal pain to your doctor. This risk is higher with weight-loss doses compared to diabetes doses.

Current evidence does not support a significant increased risk of acute pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists in human populations, despite early animal studies and spontaneous reports.

You do not need to worry about developing pancreatitis or pancreatic cancer from GLP-1 medications. Large studies have confirmed they are safe in this regard, although you should stop the medication if you experience severe abdominal pain.

Beta cell reserve and function are critical determinants of whether type 2 diabetes remission can be achieved and sustained, regardless of the amount of weight loss.

Even if you lose weight, your body's ability to produce insulin (beta cell function) determines if your diabetes goes into remission. This is why early intervention is crucial. If you have had diabetes for a long time, your beta cells may be too damaged to recover, even with significant weight loss.

Women with PCOS exhibit significantly higher basal levels of circulating miRNA-27b compared to BMI-matched healthy controls, independent of adipose tissue expression levels.

Women with PCOS have distinct molecular markers in their blood (specifically miRNA-27b) compared to healthy women of the same weight. This suggests PCOS involves specific metabolic dysregulation that is not solely explained by body fat levels.

Women experience a higher incidence of gastrointestinal adverse events (nausea, vomiting) from GLP-1 receptor agonists compared to men, even at similar drug exposure levels.

Women are more likely to experience nausea and vomiting from GLP-1 drugs than men. This is a known side effect. Use the recommended slow titration schedule to minimize these symptoms.

Tirzepatide 10mg and 15mg doses are associated with significantly higher rates of discontinuation due to adverse events compared to GLP-1 receptor agonists, primarily driven by gastrointestinal adverse events.

If you are using Tirzepatide at 10mg or 15mg, be aware that you are more likely to stop the medication due to side effects (like nausea or diarrhea) compared to using other GLP-1 drugs like semaglutide or dulaglutide. This risk is dose-dependent. If side effects become intolerable, discuss dose reduction or switching with your provider.

Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.

If you are taking a GLP-1 RA (like semaglutide or liraglutide), your common genetic risk for obesity does not predict how much weight you will lose. The drug's effectiveness is largely independent of your polygenic score for BMI or Type 2 Diabetes. Focus on adherence and lifestyle factors rather than genetic testing for treatment selection.

GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.

If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.

Metformin exerts glucose-lowering effects partly by altering gut microbiota composition to increase the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which in turn stimulate incretin hormone release.

If you take metformin, part of its benefit comes from how it changes your gut bacteria to produce beneficial compounds like butyrate. Some people experience stomach upset or gas initially, which is a known side effect linked to these microbial changes. This discomfort often improves over time.

FXR agonists (e.g., obeticholic acid) improve MASH histology but are limited by side effects like pruritus and increased LDL cholesterol.

FXR agonists like obeticholic acid can improve liver scarring and inflammation in MASH. However, they often cause severe itching and can raise bad cholesterol (LDL). They are not first-line treatments and require careful monitoring for side effects.

Obesity induces a state of CD4 T-cell exhaustion and senescence in visceral adipose tissue (VAT), characterized by persistent PD-1 expression and restricted effector function, which creates a negative legacy that persists after weight loss and contributes to treatment resistance.

If you have a history of obesity, simply losing weight may not fully reset your immune system's behavior in fat tissue. This 'immune memory' can make you more prone to inflammation and weight regain. Strategies to manage this might focus on long-term immune health and reducing chronic inflammation, rather than just short-term weight loss, as the immune system in visceral fat may remain 'exhausted' or 'senescent' even at a lower weight.

Leptin acts as a key initiator of VAT inflammation by promoting the differentiation of CD4 T cells into Th1 and Th17 subsets and inducing T-cell exhaustion via STAT3 signaling and PD-1 expression.

High levels of leptin in obesity don't just signal hunger; they actively reprogram immune cells in fat tissue to become pro-inflammatory and exhausted. This suggests that managing leptin sensitivity or levels might be important for reducing chronic inflammation associated with obesity.

Adiponectin normally suppresses VAT T-cell inflammation by inhibiting T-cell proliferation and promoting apoptosis, but its levels are reduced in obesity, thereby releasing the 'brake' on inflammatory T-cell responses.

Low levels of adiponectin in obesity remove a natural 'brake' on inflammation. Maintaining or boosting adiponectin (often through exercise and weight management) may help keep immune cells in fat tissue from becoming overly inflammatory.

Chronic inflammation in adipose tissue, driven by macrophage infiltration (M1 phenotype) and pro-inflammatory cytokine release (TNFα, IL-6), directly causes insulin resistance and contributes to the development of obesity and metabolic syndrome.

Obesity involves a biological feedback loop where excess fat tissue triggers chronic inflammation, which worsens insulin resistance and makes weight loss harder. Reducing fat mass is the most effective way to lower this inflammation and improve metabolic health, rather than just focusing on calorie counting alone.

Hypothalamic inflammation, characterized by microglial activation and increased SOCS3 expression, leads to leptin and insulin resistance in the central nervous system, promoting orexigenic signaling and weight gain.

High-fat, high-calorie diets can cause inflammation in the brain's appetite control center, blunting the 'fullness' signal. Reducing dietary quality and caloric intake can reduce this central inflammation and restore sensitivity to satiety hormones.

Metabolic surgery (specifically Roux-en-Y gastric bypass) yields higher remission rates than adjustable gastric banding, independent of the amount of weight lost.

For obese patients considering surgery, Roux-en-Y gastric bypass offers significantly higher remission rates than adjustable gastric banding, even if the weight loss is similar. This is due to hormonal changes in the gut, not just calorie restriction.

Following unaccustomed eccentric exercise, females exhibit a blunted satellite cell expansion and inflammatory gene expression (Pax7, CCL2) compared to males, suggesting a delayed or reduced myogenic response.

If you are female, your muscle may not expand its satellite cell pool as aggressively as a male's after intense eccentric exercise (like heavy downhill running or heavy eccentrics). This doesn't mean you can't build muscle, but your initial repair signaling might be different. Focus on consistent training and adequate protein intake, as your body may rely on different mechanisms for repair than males.

Exenatide does not demonstrate superior weight loss compared to placebo in adults with craniopharyngioma-related obesity when both groups receive intensive lifestyle interventions.

For adults with obesity caused by brain tumor treatment (craniopharyngioma), adding exenatide to a strict diet and exercise plan does not lead to significantly more weight loss than the diet and exercise alone. The medication may reduce hunger scores, but it does not translate to superior weight loss outcomes in this specific population.

Exenatide reduces hunger scores in adults with craniopharyngioma-related obesity, although this does not translate to significant weight loss.

Exenatide may help reduce the subjective feeling of hunger in patients with craniopharyngioma-related obesity, but this reduction in hunger does not necessarily lead to greater weight loss compared to lifestyle interventions alone.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

GLP-2 receptor activation improves intestinal barrier function and reduces systemic low-grade inflammation in obesity, but does not directly reduce appetite or body weight in humans.

GLP-2 receptor agonists (like teduglutide) are not currently recommended for weight loss in humans because they do not reduce appetite or food intake. However, they may help reduce systemic inflammation by improving gut barrier function, which is a key driver of obesity-related complications. This strategy is best used in combination with other weight-loss interventions (like GLP-1 agonists) rather than as a standalone treatment.